Topical Microemulsion Emulgel for Leflunomide Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for rheumatoid arthritis, particularly those involving leflunomide, face challenges such as hepatotoxicity, embryo-fetal toxicity, and poor solubility, which limit their long-term use and efficacy.
Innovation Solution
A topical microemulsion-based emulgel composition is developed, comprising leflunomide, a combination of surfactants (such as polysorbate 20, polyoxyl 40 hydrogenated castor oil, and PEG MW>4,000), and pharmaceutically acceptable inert excipients, to enhance solubility and skin absorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If leflunomide is administered orally for treatment of rheumatoid arthritis, then therapeutic efficacy is achieved, but hepatotoxicity and embryo-fetal toxicity occur
Solution Approach 1:
The patent applies local quality by transitioning from systemic oral administration to localized topical application. The microemulsion-based emulgel delivers leflunomide directly to the affected joints through the skin, creating a localized high concentration at the target site while maintaining lower systemic levels, thereby preserving therapeutic efficacy while reducing hepatotoxicity and embryo-fetal toxicity risks
Solution Approach 2:
The patent introduces a microemulsion-based emulgel as an intermediary delivery system. This specialized formulation acts as a mediator that enables transdermal penetration of leflunomide, facilitating controlled local delivery to inflamed joints while minimizing systemic absorption and associated adverse effects
2Duration of action of stationary object
If leflunomide is administered to achieve disease modification, then joint damage is slowed, but long-term use is limited by toxicity
Solution Approach 1:
The patent applies dynamics by enabling flexible, adjustable dosing through topical application. The emulgel formulation allows patients to apply leflunomide directly to affected areas as needed, providing dynamic control over drug delivery intensity and frequency, thereby maintaining disease modification benefits while reducing cumulative toxicity through lower overall exposure
3Quantity of substance
If conventional oral formulations are used, then systemic exposure is achieved, but solubility limitations reduce bioavailability
Solution Approach 1:
The patent applies parameter changes by fundamentally altering the physical-chemical parameters of leflunomide through microemulsion formulation. The microemulsion system changes the drug's solubility characteristics, transforming it from a poorly soluble compound to a highly soluble microemulsified form that can be effectively delivered through the skin, thereby improving both solubility and bioavailability
Solution Approach 2:
The patent employs composite materials by creating a microemulsion-based emulgel system that combines leflunomide with surfactants, co-surfactants, and gelling agents. This composite formulation integrates multiple components working synergistically to enhance drug solubility, stability, and transdermal penetration while overcoming the solubility limitations of conventional oral formulations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The microemulsion-based emulgel composition improves the solubility and skin absorption of leflunomide, reducing systemic exposure and associated side effects while maintaining therapeutic efficacy, thus offering a safer and more effective treatment option for autoimmune diseases.
Implementation Method 1
A microemulsion based emulgel composition comprising: (a) leflunomide; (b) a combination of surfactants; and (c) pharmaceutically acceptable inert excipients
Implementation Method 2
a combination of surfactants (such as polysorbate 20, polyoxyl 40 hydrogenated castor oil, and PEG MW>4,000)
Implementation Method 3
The microemulsion-based emulgel composition improves the solubility and skin absorption of leflunomide
Data Source
AI summary
The present invention relates to a composition of disease-modifying antirheumatic drugs (DMARDs) for treatment of auto-immune diseases. More particularly, the invention relates to the microemulsion based emulgel composition of DMARD-leflunomide or its derivatives for treatment of auto-immune diseases such as rheumatoid arthritis, atopic dermatitis, psoriasis and skin cancer such as melanoma, squamous cell carcinoma. The invention also discloses a method for preparation of microemulsion based emulgel composition with improved physicochemical, pharmacokinetic properties of leflunomide to be used in pharmaceutical compositions. This invention discloses the delivery of leflunomide across human skin for the treatment of autoimmune and oncological conditions. The unique delivery of leflunomide in the form of microemulsion based emulgel composition is disclosed.